Study Proves Cannabis Is A Safe Treatment As Opioid Alternative

The recent study was conducted at the St Vincent’s Hospital in Melbourne, Australia, and the Emerald Clinics (EMD) in Perth, suggests cannabis is a safe option for patients to integrate into their current pain treatment.

That includes patients who already consume high doses of opioids.

The company administered its ZTL-103, a 1:1 THC/CBD formulation to chronic pain (non-cancer) patients who used at least 60 milligrams of morphine or similar opioids daily. After a two-week dosing period, patients reported reduced levels of pain, stress, depression and anxiety, while experiencing no serious side effects.


Cronos Group just took a big leap overseas

Somewhat atypically for a marijuana stock, Cronos Group's (NASDAQ:CRON) latest growth initiative isn't an acquisition -- it's an initial public offering (IPO).

Yes, the company is already listed on the Toronto Stock Exchange and the Nasdaq, and no, it didn't float a pack of new shares on either. Rather, the company's latest stock market adventure took place far overseas. Here's the skinny about Cronos' recent involvement in an IPO, and why you might not be familiar with it.


RavenQuest receives Health Canada permit for export to Australia

Read entire article here


Why cannabinoid company Botanix rocketed 25% higher today

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been a standout performer on the Australian share market on Thursday. In morning trade the clinical stage cannabinoid company’s shares rocketed 25% higher to an all-time high of 17.5 cents.

Why did the Botanix share price rocket higher today?

Hot on the heels of a positive update on its BTX 1308 psoriasis Phase 1b mechanism of action study on Wednesday, this morning the company released an update on its BTX 1801 antimicrobial product.

According to the release, the company has received positive new data from studies recently conducted at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions.


Canadian retailer opens cannabis clinic in Australia

Canadian retailer Compass Lifestyle Clinic has opened up a dispensary in Sydney in a bid to capitalize on the underserved Australian patient demand for medicinal marijuana.

Compass was only founded last year, but it has already opened two clinics in British Columbia and six in Alberta. Another six Alberta clinics are coming soon, which will significantly boost its presence in Calgary and Edmonton.


Aphria completes second medical cannabis shipment to Australia-based partner Althea

Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE:APHA) announced that the Company has completed its second shipment of approximately 80 L (equivalent to approximately 20 kg of dried bud) of medical cannabis to its Australian-based partner Althea Company Pty Ltd.("Althea").


Lack of imports to help create cannabis shortage when Canadian recreational sales launch

International treaties, Health Canada ban on imports restrict supply from abroad.

Licensed cannabis producers are ramping up production to get ready for legalization of marijuana in Canada this year, but are also bracing for demand to far outstrip supply because of restrictions on imports.

Health Canada forbids licensed producers, which will be the only authorized sellers of marijuana to provincial governments, from importing any cannabis for sale, regardless of whether the purchase is for medical or recreational purposes.

The only cannabis imports that the department allows are those classified as genetic material for licensed dealers that conduct research and testing.


Leading small cap fund manager says this ASX medical cannabis stock has “myriad opportunities”

The top performing OC Micro-Cap Fund has said cashed-up Cann Group Ltd (ASX:CAN) has “myriad opportunities” in the fast developing medical cannabis industry, saying the company has “a clear path to profitability.”


Moncton-based Organigram hopes to take its cannabis business global

After getting licence to export medical cannabis, company plans 1st shipment to Australia.

Organigram, the Moncton-based medical cannabis company, is taking its business international, which could mean more jobs in New Brunswick down the road. 

The company has received a licence from Health Canada to export its products.

Organigram said it plans to send its first shipment to Australia next week.

It also recently signed a contract for an equity stake in a German medical cannabis company.

Ray Gracewood, chief commercial officer for Organigram, told Information Morning Moncton the international market presents a "massive" opportunity to grow the company.


Canopy Growth launches spectrum Australia with support from the Victoria State government

Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to join the Victoria State Government in announcing the launch of the newest member of the Canopy Growth family, Spectrum Cannabis Australia ("Spectrum" or "Spectrum Australia").

Minister for Agriculture, the Hon. Jaala Pulford, alongside Ben Quirin, Managing Director of Spectrum Australia, announced the Company will invest up to $16 millionAUD (~$16 million CAD) in the State of Victoria over the next four years to establish Spectrum's Asia-Pacific (APAC) headquarters and research and development facility.


Subscribe to RSS - Australia